Search 

Enso Ventures is a Venture Capital firm that was founded in 2010 and based in London with an additional office in New York. The firm is looking to provide equity capital to high growth companies in the life science space. The firm is currently interested in companies located in Europe, Russia and the US and is looking to make approximately 2-3 investments over the next 6-9 months.

Excel Venture Management is a venture capital firm that was founded in 2008 and is based in Boston, Massachusetts. The firm has managed one fund with committed capital of $125 million, and the firm is currently raising the second fund. Excel Venture Management seeks to make equity investments into life science companies from early to late stages. The typical investment size ranges from $3 million to $ 5million. The firm plans to invest in 4-5 companies over the next 6-9 months and prefers to invest in companies based in US.

Formula Pharmaceuticals is a US-based oncology focused biotech company, developing Chimeric Antigen Receptor (CAR) based therapies using a proprietary platform.

Formula's CAR therapies involve allogeneic immune effector cells and a NON-viral transfection method for highly efficient cell expansion and differentiation. Additionally, Formula's target effector cells primarily involve Cytokine Induced Killer cells, instead of T-cells or Natural Killer cells. These various characteristics offer distinct practical, clinical, regulatory and commercial benefits over other CAR approaches that involve autologous cells and viral transfection methods. Although not yet in clinical stage development, Formula believes that its CAR based development program will catch up with competing clinical-stage development programs, based on the significant CMC and regulatory advantages that Formula's CAR approach offers.

Formula is interested in meeting with investors and prospective pharmaceutical/biotech partners. Near-term value driving milestones (including clinical trial results) are expected within the next 2-3 years.

Significant industry and investor interest in CAR based therapies have been established over the past 12 months, with 4 leading industry players (Pfizer; Novartis; Celgene and Juno Therapeutics). Formula's CAR therapy is distinctive, and is believed to offer significant advantages of the aforementioned CAR technologies. CARs represent a new and important paradigm for cancer therapy, with the leading pharmaceutical players expected to acquire and develop their own position into this space.

Horizon Technology Finance is a venture lending, investment and financial services management company that was founded in 2003 and is headquartered in Farmington, Ct with additional offices in Walnut Creek, CA and Reston, VA. The firm controls approximately $200 million in assets under management and look to provide senior or subordinate loans to companies in the range of $2 to $20 million dollars, and often syndicates much larger deals. The firm prefers to lead or co-lead investments that they are involved in and looks to be involved in 15 deals in the next 6-9 months. The firm provides capital to companies located throughout the United States and Canada.